AIO-STO-0321 - PHERFLOT Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT – Pembrolizumab und Trastuzumab in Kombination mit FLOT in der perioperativen Behandlung von HER2-positivem, lokalisiertem gastroösophagealem Adenokarzinom – Eine Phase-II-Studie der AIO-Studiengruppe (Aktiv)
AIO-STO-0417- MOONLIGHT Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX or with modified FOLFOX plus Nivolumab and Ipilimumab. The groups will be compared for time until progression of the disease (primary endpoint) as well as for response to the treatment, overall survival, safety/tolerability of the treatment and quality of life (Aktiv)
Amgen 20210098 - FORTITUDE-102 Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (Aktiv)
CA209-649 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (Aktiv)
COMPETE Eine prospektive, randomisierte, kontrollierte, offene, multizentrische Phase III Studie zur Beurteilung der Wirksamkeit und Sicherheit der Peptid-Rezeptor-Radionuklid-Therapie (PRRT) mit 177Lutetium-Edotreotid im Vergleich zur gezielten molekularen Therapie mit Everolimus bei Patienten mit inoperablen, progressiven, Somatostatin-Rezeptor positiven (SSTR +), neuroendokrinen Tumoren des Magen-Darm Trakts oder pankreatischen Ursprungs (GEP-NET) (Aktiv)
ESOPEC Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (Aktiv)
KEYMAKER MK3475-06A Protocol Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A (Aktiv)
MEMORI Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (Aktiv)
MK7902-015 Eine randomisierte Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapie im Vergleich zur Standardtherapie als Erstlinienintervention bei Teilnehmern mit fortgeschrittenem/metastasierendem gastroösophagealem Adenokarzinom (LEAP-015) (Aktiv)
OPPOSITE Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen. (Aktiv)
SPOT Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus (Aktiv)
Zweitlinie oder später
AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer (Aktiv)
AMG910 Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (Aktiv)
CVPM087A2101 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (Aktiv)
Destiny 03 Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (Aktiv)
EORTC Vestige Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) (Aktiv)
FLOT 9 HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) (Aktiv)
I4T-NS-O038 - RE-ExPEL Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (Aktiv)
INTEGRATE IIb Studie To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC. (Aktiv)
LIBRETTO-001 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)
MAGIC A randomized, double-blind, trial to evaluate the safety and efficacy of apraglutide in Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy (TA799-101) (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)
Novartis CFKA115A12101 A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers (Aktiv)
RACE Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ (Aktiv)
RAMIRIS_AIO STO 0415 Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Gastric Cancer (Aktiv)